全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2018 

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis

DOI: 10.1177/1759720X17752037

Keywords: Rheumatoid arthritis, interleukin-6, sarilumab, biologic DMARD

Full-Text   Cite this paper   Add to My Lib

Abstract:

The mainstay of rheumatoid arthritis (RA) treatment involves the use of medications that slow disease progression and reduce inflammation. Inadequate treatment responses and intolerances to conventional RA treatment have led to the development of biologic agents for the management of moderate-to-severe disease activity. Interleukin-6 (IL-6) inhibition is one of the targets for biologic activity in RA treatment. IL-6 is found in excess in the synovial fluid and contributes to joint erosion through its action on osteoclast cells. Sarilumab is a new IL-6 inhibitor indicated for the treatment of moderate-to-severe RA as monotherapy or in combination with conventional therapies in patients with an inadequate response to previous RA treatment

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133